Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Jefferies Group raised their Q3 2017 earnings estimates for shares of Supernus Pharmaceuticals in a report issued on Monday. Jefferies Group analyst D. Steinberg now forecasts that the specialty pharmaceutical company will earn $0.27 per share for the quarter, up from their prior estimate of $0.24. Jefferies Group currently has a “Buy” rating and a $51.00 price objective on the stock. Jefferies Group also issued estimates for Supernus Pharmaceuticals’ FY2017 earnings at $1.01 EPS and FY2018 earnings at $1.61 EPS.
Other analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 target price for the company in a research note on Thursday, July 13th. Cantor Fitzgerald boosted their price target on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a research report on Wednesday, July 5th. BidaskClub lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Stifel Nicolaus restated a “buy” rating and set a $47.00 price target (up from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Finally, Piper Jaffray Companies lowered shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $46.00 price target on the stock. in a research report on Monday, July 17th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Supernus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $48.43.
Shares of Supernus Pharmaceuticals (SUPN) opened at 41.70 on Tuesday. Supernus Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $44.95. The firm has a 50-day moving average price of $42.46 and a 200-day moving average price of $33.49. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of 21.05 and a beta of 1.31.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The business had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million.
In related news, VP Padmanabh P. Bhatt sold 3,735 shares of the business’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total transaction of $167,701.50. Following the transaction, the vice president now directly owns 21,209 shares in the company, valued at $952,284.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,500 shares of the business’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the transaction, the vice president now owns 37,500 shares in the company, valued at $1,346,250. The disclosure for this sale can be found here. Insiders have sold 24,291 shares of company stock worth $962,766 over the last 90 days. 6.70% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of SUPN. BlackRock Inc. increased its stake in Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after buying an additional 6,692,025 shares in the last quarter. Emerald Advisers Inc. PA purchased a new stake in Supernus Pharmaceuticals during the second quarter worth about $21,474,000. Emerald Mutual Fund Advisers Trust purchased a new stake in Supernus Pharmaceuticals during the second quarter worth about $17,553,000. Hodges Capital Management Inc. purchased a new stake in Supernus Pharmaceuticals during the second quarter worth about $17,220,000. Finally, Rice Hall James & Associates LLC increased its stake in Supernus Pharmaceuticals by 24.5% in the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock worth $58,675,000 after buying an additional 267,971 shares in the last quarter. Hedge funds and other institutional investors own 94.39% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.